DuoDote Nerve Agent Antidote Autoinjector

The Office of Acquisitions Management (AQM), U.S. Department of State (State), is seeking sources capable of providing the DuoDote Nerve Agent Auto-Injector (DuoDote). State is contemplating awarding a one-year base and four one-year option, indefinite delivery, indefinite quantity contract fo DuoDote. The quantities to be ordered are estimated at 100,000 units minimum and 500,000 units maximum over the entire duration of the contract. However, the quantity may increase or decrease as State's requirements change.

The DuoDote shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration.

Must have FDA approval to sell the DuoDote before award of the contract.

If your firm currently manufactures or distributes the DuoDote, please provide information with respect to the following:
a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price

f) Estimated inventory level and storage requirements

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the DuoDote or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to AQM.
Data obtained from this Request For Information (RFI) will be used by AQM in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the DuoDote. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.

Your response to this RFI should be submitted electronically in pdf format by August 11, 2023 1:00pm EDT.